DOI: 10.5281/zenodo.21249240

View latest PathMap Research

DISCLAIMER: This data is not peer reviewed and is NOT professional advice.
Original Text Evaluated

Can BMAA, a known glutamate mimic, cause hyperexcited retinal ganglion cells and cause them to "misfire" corollary discharge?

Plausibility Verdicts

Evaluation 1

There is no evidence that BMAA causes RGC-mediated misfiring of corollary discharge signals; RGCs are generally resilient to BMAA excitotoxicity.

Evaluation 2

No existing evidence links BMAA to the disruption of retinal corollary discharge.

Evaluation 3

No direct evidence links BMAA to corollary discharge misfiring, although BMAA is proven to cause retinal excitotoxicity and neurodegeneration.

Dataset Summary

Novel & Overlooked Insights

  • BMAA toxicity in the retina is cell-type specific: amacrine neurons are highly sensitive to NMDA-mediated death, while photoreceptors are largely resistant to NMDA antagonists.
  • Retinal Ganglion Cells (RGCs) exhibit significant resilience to NMDA excitotoxicity, an observation that distinguishes them from other retinal populations.
  • Corollary discharge signaling is vital for visual stability and involves the "cancellation" or "ignoring" of self-generated retinal motion caused by eye movements.
  • The "blank effect" in eye-tracking studies indicates the availability of extraretinal signals for perceptual judgements, even after damage to cortical areas like the posterior parietal cortex.
  • BMAA can induce ALS/MND-type pathological changes, including TDP-43 proteinopathy, which may be modulated by L-serine administration.
  • The role of extraretinal signals in MSTd heading tuning is surprisingly limited in comparison to retinal-based corrections for pursuit eye movements.
  • Pre-saccadic attention shifts, a function related to corollary discharge, appear largely intact in individuals with schizophrenia, despite widespread assumptions of corollary discharge dysfunction.
  • The "blank effect" demonstrates that even with PPC lesions, corollary discharge influence on perception is not fully abolished.
  • Saccadic suppression and visual stability are functionally dissociable, as shown in double-step saccade paradigms.
  • There is a transition in spino-ocular motor coupling during development, indicating that corollary discharge pathways undergo significant remodeling.
  • BMAA exposure leads to the accumulation of TDP-43 and α-synuclein, bridging cyanobacterial toxicity with established ALS and Parkinson's disease proteinopathies.
  • RXR activation with the agonist HX630 provides a potential broad-spectrum neuroprotective strategy against BMAA-induced retinal degeneration.
  • The toxicity mechanism in the retina varies by cell type; NMDA receptor activation is a specific feature of amacrine cell death but is not universally present in all retinal cell types affected by BMAA.
  • Glutamatergic synaptic disruption in the retina is an early event in several degenerative conditions and is linked to the downstream failure of blood-retinal barrier maintenance.
  • BMAA acts via polyADP ribose polymerase (PARP) activation, a pathway that can be modulated to preserve retinal structure.
  • Oxidative stress and mitochondrial bioenergetic collapse are central themes in BMAA-induced pathology.
  • The interaction between metabolic rate and visual perception pathways suggests that domestication or environmental stress in fish models may be influenced by specific retinal G protein-coupled receptors.
  • Zinc homeostasis, while potentially critical, is highlighted in the context of ALS but remains under-explored in the specific context of BMAA-driven RGC synaptic activity.
  • BMAA can cause "nuclear fragmentation and cell death in both photoreceptors (PHRs) and amacrine neurons, provoking mitochondrial membrane depolarization."
  • Carbamate adducts of BMAA, rather than BMAA itself, are suggested as the primary modulators of GluR2 receptors.
  • RXR activation has shown potential to prevent BMAA-induced retinal cell death by reducing reactive oxygen species.
  • BMAA can cross the blood-brain barrier via olfactory pathways, potentially explaining site-specific neurodegeneration.
  • Metabolic profiling of zebrafish embryos shows that BMAA induces "metabolic reprogramming" and lipid biosynthetic inhibition.
  • L-serine, but not traditional antioxidants, provides protection against BMAA-induced proteotoxic stress in certain cell lines.
  • BMAA can inhibit vesicular monoamine transporter 2 (VMAT2), preventing the uptake of monoaminergic neurotransmitters.

Extracted Discoveries

Suggested Experiments
  • Test RGC activity patterns under chronic BMAA exposure using MEAs to check for spontaneous discharge anomalies.
  • Measure corollary discharge integrity in behavioral tasks using BMAA-exposed animal models.
  • Perform whole-cell patch-clamp recordings on RGCs under BMAA exposure to determine changes in membrane potential and firing rate.
  • Use optogenetic stimulation of retinal circuits to observe if BMAA interferes with the timing of inhibitory inputs typically associated with corollary discharge.
  • Assess corollary discharge-related neuronal firing patterns in RGCs using electrophysiology after chronic BMAA exposure.
  • Evaluate if NMDA antagonists effectively modulate RGC firing during antisaccade tasks in BMAA-treated animal models.
Suggested Studies
  • Cross-sectional assessment of corollary discharge stability in patients exposed to dietary BMAA sources.
  • Longitudinal study of RGC synaptic plasticity following BMAA-induced glial activation.
  • Longitudinal behavioral study of zebrafish exposed to BMAA during development to assess visual processing feedback loops.
  • Proteomic analysis of synaptosomes isolated from BMAA-treated retina to identify potential RGC signaling protein modifications.
  • Investigate the impact of BMAA on the molecular integrity of the presynaptic amacrine-to-RGC synapse to determine potential loss of inhibitory signal gating.
  • Examine if BMAA-induced mitochondrial dysfunction in RGCs correlates with shifts in temporal sensitivity during saccadic eye movements.
Swansons Literature Based Discovery Candidates
  • Discovered Hypothesis (A to C): Chronic BMAA exposure may induce long-term visual instability in humans by altering the threshold of corollary discharge suppression in the optic pathway. - Literature A (Origin): BMAA induced neuro-inflammation and neurodegenerative pathology (ID: 32077471, 39159686). - Literature C (Target): Corollary discharge suppression is essential for maintaining stable vision during active displacement (ID: 36569798). - The Intersecting Bridge B: Microglial regulation of synaptic plasticity and neurotransmitter balance (ID: 42292332). - Biological Rationale: BMAA activates microglial pro-inflammatory pathways (e.g., NLRP3), and since microglia regulate synaptic plasticity that sustains the neural circuits forcorollary discharge, neuroinflammation may weaken the fidelity of the motor-visual prediction.
  • Discovered Hypothesis (A to C): BMAA exposure may drive TDP-43 aggregation in retinal ganglion cells via the inhibition of mitochondrial mitophagic clearance (mediated by PINK1/Parkin or AMPK signaling).
    Literature A (Origin): BMAA-induced accumulation of TDP-43 and autophagic impairment (Source: 38596666).
    Literature C (Target): Mitophagic clearance of Aβ-damaged mitochondria via AMPK/Beclin1 (Source: 42333946).
    The Intersecting Bridge B: AMPK-dependent signaling pathways.
    Biological Rationale: BMAA is established to impair autophagy and mitochondrial function; if this impairment involves the same AMPK/Beclin1 pathway that rescues Aβ-induced damage, then pharmacological activation of this specific bridge could reverse BMAA-induced TDP-43 aggregation.
  • BMAA induces retinal hyperexcitability that selectively impairs the inhibition of corollary discharge by affecting the inhibitory amacrine cell inputs.
  • BMAA toxicity induces retinal ganglion cell excitotoxicity (ID 33144094).
  • The temporal precision of corollary discharge depends on inhibitory signals in the visual circuit (ID 42202781).
  • GABAergic amacrine cell signaling.
  • Since BMAA impairs retinal neurons and disrupts synaptic inhibition, it may specifically target the GABAergic inhibitory pathways required for the accurate gatekeeping of corollary discharge signals during retinal activity.
Contradictions Between Evidences
  • There is a minor contradiction in the role of NMDARs in RGC map formation; while pharmacological inhibition suggested dependence, subsequent conditional genetic knockout of GluN1 demonstrated that NMDAR expression on RGCs is not an absolute requirement (ID 34193509 vs early pharmacologic studies).
  • None identified in the current set; evidence consistently points toward BMAA causing retinal degeneration through distinct mechanisms (e.g., NMDA activation in amacrine cells vs. proteinopathy and ROS in others).
  • None identified; however, behavioral deficits in zebrafish are inconsistent across different experimental protocols, likely due to varying concentrations and developmental stages.
Repurposed Solutions
  • L-Serine, shown to reduce BMAA-induced proteinopathy (ID 32077471), could be evaluated as a prophylactic agent for visual path protection in populations exposed to environmental cyanotoxins.
  • The use of RXR agonists (like HX630) or AMPK-activating agents (like Humanin) represent repurposed potential therapeutics that could address the mitochondrial and autophagic dysfunction induced by BMAA in retinal neurons.
  • 5-HT1A receptor antagonists (e.g., WAY-100635) and RXR agonists (e.g., HX630) are potential candidates for mitigating BMAA-induced RGC metabolic stress and excitotoxicity.
Support open science: Order your own dataset here.

Perfect for thesis ideas and a base concept for academic writings!

Each package comes with guaranteed unpublished discoveries!

Order now - $29.99

PathMap is funded by sales of datasets and coversheets to researchers of any kind who wish to discover the most viable routes and paths to accelerate cures. We do not make theoretical molecules, we expose the truth in current PubMed literature. Commission a trace today.

Investigator Profile

👨‍🔬
Joshua Dungan
PathMap Admin
PathMap PathMap Image